Lorcaserin vs. PHENTERMINE (cas 122-09-8) among non-surgical and surgical obese patients: Anthropometric, glycemic, lipid, safety and cost outcomes
-
Add time:09/05/2019 Source:sciencedirect.com
BackgroundTo evaluate effectiveness, safety, and costs of Lorcaserin vs. PHENTERMINE (cas 122-09-8) among obese non–surgical and surgical patients (post bariatric surgery).
We also recommend Trading Suppliers and Manufacturers of PHENTERMINE (cas 122-09-8). Pls Click Website Link as below: cas 122-09-8 suppliers
Prev:Letter to the EditorPHENTERMINE (cas 122-09-8) associated recurrent intracerebral hemorrhage
Next:Case reportPHENTERMINE (cas 122-09-8) and Coronary Vasospasm–Induced Myocardial Infarction) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Study protocol and rationale for a randomized double-blinded crossover trial of PHENTERMINE (cas 122-09-8)-topiramate ER versus placebo to treat binge eating disorder and bulimia nervosa09/25/2019
- Case ReportParadoxical topiramate-induced hyperphagia successfully treated with PHENTERMINE (cas 122-09-8) in a woman with migraine09/24/2019
- Clustering of PHENTERMINE (cas 122-09-8) HCL Drug from Online Patient Medication Reviews09/10/2019
- Original articleUse of PHENTERMINE (cas 122-09-8)-topiramate extended release in combination with sleeve gastrectomy in patients with BMI 50 kg/m2 or more09/09/2019
- Clinical ScienceEffects of liraglutide plus PHENTERMINE (cas 122-09-8) in adults with obesity following 1 year of treatment by liraglutide alone: A randomized placebo-controlled pilot trial09/08/2019
- PHENTERMINE (cas 122-09-8)☆09/07/2019
- Case reportPHENTERMINE (cas 122-09-8) and Coronary Vasospasm–Induced Myocardial Infarction09/06/2019
- Letter to the EditorPHENTERMINE (cas 122-09-8) associated recurrent intracerebral hemorrhage09/04/2019